English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
New Agent Reduces Eye Bulging in Graves’ Orbitopathy, Offering New Hope for Patients
An experimental human monoclonal antibody dramatically reduced the most debilitating symptoms of Graves’ orbitopathy, including proptosis and double vision, giving new hope to patients that a treatment for thyroid eye disease may finally be within reach, according to a speaker at the AACE Annual Scientific and Clinical Congress.
According to new phase 3 data from the OPTIC trial presented here, adults with active Graves’ orbitopathy treated with teprotumumab (Horizon Pharma) for 21 weeks experienced an average proptosis reduction of 2.82 mm at 24 weeks compared with an average of 0.54 mm for those assigned to placebo, with between-group differences in proptosis reduction observed at all study time points, according to Raymond Douglas, MD, PhD, Director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center. Other symptoms associated with the disease, including inflammation, pain, swelling and redness, were also reduced for patients assigned teprotumumab vs. placebo, he said.
myBinderRelated Content
-
University of Miami Health SystemWe leverage the latest research complete...
-
Quality-of-Life Impairments Persist Six Months After Treatment of Graves’ Hyperthyroidism and Toxic Nodular Go...Background: The treatment of hyperthyro...
-
The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...
-
Thyroidectomy as Primary Treatment Optimizes Body Mass Index in Patients With HyperthyroidismObjective: The purpose of this study wa...
-
New Therapeutic Horizons for Graves’ HyperthyroidismGraves’ hyperthyroidism is characteriz...
-
Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves’ Disease By Early Initiatio...Background: Radioactive iodine (RAI) th...
-
Should I Consider Thyroidectomy for Graves’ Disease?https://www.youtube.com/watch?v=HuodaiVD...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
